Katarzyna Kazmierczak Selected Research

Myosin Light Chains (Myosin Essential Light Chain)

1/2021	Hypertrophic cardiomyopathy associated E22K mutation in myosin regulatory light chain decreases calcium-activated tension and stiffness and reduces myofilament Ca2+ sensitivity.
1/2020	Ablation of the N terminus of cardiac essential light chain promotes the super-relaxed state of myosin and counteracts hypercontractility in hypertrophic cardiomyopathy mutant mice.
1/2019	Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains.
1/2019	Phosphomimetic-mediated in vitro rescue of hypertrophic cardiomyopathy linked to R58Q mutation in myosin regulatory light chain.
8/2017	Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice.
1/2017	Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice.
1/2016	Gene expression patterns in transgenic mouse models of hypertrophic cardiomyopathy caused by mutations in myosin regulatory light chain.
12/2015	Proteomic analysis of physiological versus pathological cardiac remodeling in animal models expressing mutations in myosin essential light chains.
6/2015	Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain.
1/2015	A Novel Method of Determining the Functional Effects of a Minor Genetic Modification of a Protein.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katarzyna Kazmierczak Research Topics

Disease

13	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2021 - 02/2012
9	Familial Hypertrophic Cardiomyopathy (Cardiomyopathy, Familial Hypertrophic) 12/2014 - 03/2009
5	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2009
4	Cardiomegaly (Heart Hypertrophy) 01/2021 - 02/2012
3	Heart Diseases (Heart Disease) 01/2021 - 07/2015
3	Hypertrophy 12/2015 - 02/2012
2	Muscular Diseases (Myopathy) 12/2020 - 01/2019
1	Disease Progression 01/2021
1	Stroke (Strokes) 12/2020
1	Muscle Weakness 01/2019
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2018
1	Restrictive Cardiomyopathy 08/2017
1	familial dilated cardiomyopathy 06/2015
1	Lymphoma (Lymphomas) 06/2011
1	Dementia (Dementias) 10/2007
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2007
1	Inflammation (Inflammations) 10/2007

Drug/Important Bio-Agent (IBA)

15	Myosin Light Chains (Myosin Essential Light Chain)IBA 01/2021 - 10/2010
12	Myosins (Myosin)IBA 01/2022 - 01/2009
9	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2010
7	Ventricular MyosinsIBA 01/2021 - 03/2009
4	Cardiac MyosinsIBA 01/2021 - 07/2015
4	Alanine (L-Alanine)FDA Link 12/2015 - 12/2011
2	Arginine (L-Arginine)FDA Link 01/2019 - 01/2015
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 08/2013 - 12/2011
2	Valine (L-Valine)FDA Link 04/2012 - 03/2009
2	Aspartic Acid (Aspartate)FDA Link 04/2012 - 03/2009
1	MYK-461IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	CalciumIBA 01/2021
1	Protein Isoforms (Isoforms)IBA 12/2020
1	Adenosine Triphosphate (ATP)IBA 12/2020
1	Glutamine (L-Glutamine)FDA Link 01/2019
1	Polymethyl Methacrylate (Sol)IBA 01/2019
1	sarcalumeninIBA 12/2015
1	Carrier Proteins (Binding Protein)IBA 12/2015
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2015
1	Myosin-Light-Chain KinaseIBA 07/2015
1	Threonine (L-Threonine)FDA Link 01/2015
1	Troponin IIBA 01/2015
1	Cysteine (L-Cysteine)FDA Link 01/2015
1	Antiviral Agents (Antivirals)IBA 10/2007

Therapy/Procedure

1	Therapeutics 01/2021